← Leaderboards
Pui-Kai Li
University Of California At Davis
$1,169,912
Attributed
$2,339,824
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $610.3K · FY2022–25$1M$750K$500K$250K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$2,339,824 · 1
By mechanism
R01$2,339,824 · 1
Top collaborators
- Allen C Gao7 shared
Most similar at University Of California At Davis
Same institution · by research overlap
- Allen C Gao$13,767,104
- Hongwu Chen$9,989,556
- Alan Lombard$832,680
- Nagalakshmi Nadiminty$524,556
Others in their field
Other Rising Stars on “Inhibitor”
- Supriya Menezes · The Emmes Company, Llc$25,277,032
- Michael Difilippantonio · Leidos Biomedical Research, Inc.$22,364,766
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
- Michael George Natchus · Emory University$10,548,554
- John Alam · Eip Pharma, Inc.$10,411,018
- Kenneth Schultz · Trethera Corporation$8,384,949
Research focus
InhibitorMetabolismFamilyGenesLibrariesMemberDrug KineticsEnzyme ActivityFutureAndrogensIn VivoAbirateroneAndrogen AntagonistsCell CountAndrogen ReceptorDoseAdvanced Prostate CancerEnzalutamideAutomobile DrivingDesignClinical DevelopmentComputer ModelsAndrostenedioneNeoplastic Cell
Grant awards (7)
Novel therapeutics dual targeting intracrine androgen synthesis and AR for advanced prostate cancer$521,811
R01 · FY2025 · CA
Novel therapeutics dual targeting intracrine androgen synthesis and AR for advanced prostate cancer$88,514
R01 · FY2025 · CA
Novel therapeutics dual targeting intracrine androgen synthesis and AR for advanced prostate cancer$507,346
R01 · FY2024 · CA
Novel therapeutics dual targeting intracrine androgen synthesis and AR for advanced prostate cancer$83,979
R01 · FY2024 · CA
Novel therapeutics dual targeting intracrine androgen synthesis and AR for advanced prostate cancer$521,104
R01 · FY2023 · CA
Novel therapeutics dual targeting intracrine androgen synthesis and AR for advanced prostate cancer$73,643
R01 · FY2023 · CA
Novel therapeutics dual targeting intracrine androgen synthesis and AR for advanced prostate cancer$543,427
R01 · FY2022 · CA